Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer

Future Oncology

Volumn 9, Issue 9, 2013, Pages 1375-1388

  Cardillo, Irene ^a   Spugnini, Enrico P ^a   Galluzzo, Paola ^a   Contestabile, Michela ^a   Dellanna, Maria Lucia ^b   Picardo, Mauro ^b   Crispi, Stefania ^c   Calogero, Raffaele A ^d   Piccolo, Maria Teresa ^c   Arigoni, Maddalena ^d   Cantarella, Daniela ^e   Boccellino, Mariarosaria ^f   Quagliuolo, Lucio ^f   Ferretti, Gianluigi ^a   Carlini, Paolo ^a   Felici, Alessandra ^a   Boccardo, Francesco ^g   Cognetti, Francesco ^a   Baldi, Alfonso ^f  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e CANDIOLO CANCER INSTITUTE   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

array; cyclophosphamide; docetaxel; genomic expression; prostate cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; INTERLEUKIN 6; PROTEIN P21; PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; METRONOMIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; UPREGULATION;

AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAXOIDS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883295064     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.99     Document Type: Article

References (39)

1. Itsiopoulos C, Hodge A, Kaimakamis M. Can the Mediterranean diet prevent prostate cancer? Mol. Nutr. Food Res. 53, 227-239 (2009
2. Kaliks RA, Del Giglio A. Management of advanced prostate cancer. Rev. Assoc. Med. Bras. 54, 178-182 (2008
3. Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004
5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010
6. Ryan CJ, Smith MR, deBono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013
7. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376, 1147-1154 (2010
8. de Bono JS, Logothetis CJ, Fizaki K et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301. A randomized double-blind placebo-controlled Phase 3 study. Ann. Oncol. 2010b(21), Abstract LBA5 (2010
9. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012
10. Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143, 401-409 (1993
11. Shariat SF, Anwuri VA, Lamb DJ et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J. Clin. Oncol. 22, 1655-1663 (2004
12. Man S, Bocci G, Francia G et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62, 2731-2735 (2002
13. Shaked Y, Emmenegger U, Francia G et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 65, 7045-7051 (2005
14. Emmenegger U, Francia G, Shaked Y, Kerbel RS. Metronomic chemotherapy: Principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results Cancer Res. 180, 165-183 (2010
15. Nelius T, Rinard K, Filleur S. Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: Review of the literature. Cancer Treat. Rev. 37, 444-455 (2011
16. Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63, 4342-4346 (2003
17. Bocci G, Francia G, Man S et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl Acad. Sci. USA 100, 12917-12922 (2003
18. Baldi A, Mottolese M, Vincenzi B et al. The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics 9, 1069-1077 (2008
19. Severino A, Campioni M, Straino S et al. Identification of protein disulfide isomerase (PDI) as a cardiomyocyte survival factor during the development of human ischemic cardiomyopathy. J. Am. Coll. Cardiol. 50, 1029-1037 (2007
20. Conesa A, Nueda MJ, Ferrer A, Talón M. maSigPro: A method to identify significantly differential expression profiles in time-course microarray experiments. Bioinformatics 22, 1096-1102 (2006
21. Sanges R, Cordero F, Calogero RA. oneChannelGUI: A graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language. Bioinformatics 23, 3406-3408 (2007
22. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4(6), 423-436 (2004
23. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3(2), 147-158 (1999
24. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648 (2007
25. Wada S, Yoshimura K, Hipkiss EL et al. Cyclophosphamide augments antitumor immunity: Studies in an autochthonous prostate cancer model. Cancer Res. 69, 4309-4318 (2009
26. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother. 58, 1627-1634 (2009
27. Chen CA, Ho CM, Chang MC et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol. Ther. 18, 1233-1243 (2010
28. Ghiringhelli F, Menard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-b-dependent manner. J. Exp. Med. 202, 1075-1085 (2005
29. Sancéau J, Wietzerbin J. Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon-alpha or interferon-beta with ifosfamide. Ann. NY Acad Sci. 1030, 170-178 (2004
30. Hervonen P, Tulijoki T, Kellokumpu Lehtinen P. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer. Anticancer Res. 32, 3305-3309 (2012
31. Wegiel B, Bjartell A, Culig Z, and Persson JL. Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int. J. Cancer 122, 1521-1529 (2008
32. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 5, 1403-1413 (2009
33. Starsíchová A, Lincová E, Pernicová Z et al. TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. Cell Signal. 22, 1734-1744 (2010
34. Hurria A, Fleming MT, Baker SD et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin. Cancer Res. 12, 6100-6105 (2006
35. Baker SD, Zhao M, Lee CK et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin. Cancer Res. 10(6), 1976-1983 (2004
36. Cumashi A, Tinari N, Rossi C et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett. 270, 229-233 (2008
37. Raghavan D, Cox K, Pearson BS et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br. J. Urol. 72, 625-628 (1993
38. Lord R, Nair S, Schache A et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer:a Phase II study. J. Urol. 177, 2136-2140 (2007
39. Nicolini A, Mancini P, Ferrari P et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed. Pharmacother. 58, 447-450 (2004